Glenmark Pharmaceuticals on Wednesday announced its foray into the branded dermatology segment in the United States.
The branded portfolio for the US market will be developed and commercialised by Glenmark Therapeutics Inc USA, Glenmark Pharmaceu-ticals said in a regulatory filing.
“This represents an important step in the company’s long-term strategy to build a robust branded business in the US, alongside the company’s existing and successful generics business,” the company added.
Glenmark is already present in generic dermatology market in the US. Glenmark Therapeutics recently acquired the rights to seven branded dermatology products from Exeltis USA, Inc. The cumulative sales of the seven acquired brands were USD 9 million.
“All the acquired products are currently approved and marketed in the US, giving Glenmark Therapeutics an immediate entry into the topical branded products segment. In addition, Glenmark Therapeutics intends to launch other branded dermatology products over the next 12 months,” Glenmark said.